Targeting receptor activator of nuclear factor kappa-B ligand (RANKL) may have advantages in DMD by ameliorating dystrophic skeletal muscle function in addition to their bone anti-resorptive properties. This evidence concerns the gene TNFSF11 and Duchenne muscular dystrophy.